Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Meta-analysis: anti-BCMA CAR-T in R/R myeloma

Nico Gagelmann • 1 Sep 2020
EBMT 2020
Multiple Myeloma CAR-T

Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the results from the meta-analysis evaluating the outcomes of anti-BCMA CAR T-cell therapy in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Nico Gagelmann

4:18
CAR T-cells: current climate & future perspectives in myeloma
Nico Gagelmann • 1 Sep 2020

Related Videos

2:47
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Sergio Giralt • 17 Feb 2023
1:05
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA
Hermann Einsele • 10 Feb 2023
2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
2:45
Phase I study of CC-98633 in R/R multiple myeloma
Luciano Costa • 11 Dec 2022
The content of VJRegenMed is intended for healthcare professionals